Therapeutic Potential and Mechanisms of Novel Simple O-Substituted Isoflavones against Cerebral Ischemia Reperfusion

Int J Mol Sci. 2022 Sep 8;23(18):10394. doi: 10.3390/ijms231810394.

Abstract

Isoflavones have been widely studied and have attracted extensive attention in fields ranging from chemotaxonomy and plant physiology to human nutrition and medicine. Isoflavones are often divided into three subgroups: simple O-substituted derivatives, prenylated derivatives, and glycosides. Simple O-substituted isoflavones and their glycosides, such as daidzein (daidzin), genistein (genistin), glycitein (glycitin), biochanin A (astroside), and formononetin (ononin), are the most common ingredients in legumes and are considered as phytoestrogens for daily dietary hormone replacement therapy due to their structural similarity to 17-β-estradiol. On the basis of the known estrogen-like potency, these above isoflavones possess multiple pharmacological activities such as antioxidant, anti-inflammatory, anticancer, anti-angiogenetic, hepatoprotective, antidiabetic, antilipidemic, anti-osteoporotic, and neuroprotective activities. However, there are very few review studies on the protective effects of these novel isoflavones and their related compounds in cerebral ischemia reperfusion. This review primarily focuses on the biosynthesis, metabolism, and neuroprotective mechanism of these aforementioned novel isoflavones in cerebral ischemia reperfusion. From these published works in in vitro and in vivo studies, simple O-substituted isoflavones could serve as promising therapeutic compounds for the prevention and treatment of cerebral ischemia reperfusion via their estrogenic receptor properties and neuron-modulatory, antioxidant, anti-inflammatory, and anti-apoptotic effects. The detailed mechanism of the protective effects of simple O-substituted isoflavones against cerebral ischemia reperfusion might be related to the PI3K/AKT/ERK/mTOR or GSK-3β pathway, eNOS/Keap1/Nrf-2/HO-1 pathway, TLRs/TIRAP/MyD88/NFκ-B pathway, and Bcl-2-regulated anti-apoptotic pathway. However, clinical trials are needed to verify their potential on cerebral ischemia reperfusion because past studies were conducted with rodents and prophylactic administration.

Keywords: biosynthesis; cerebral ischemia reperfusion; isoflavones; metabolism.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Brain Ischemia* / drug therapy
  • Estradiol
  • Estrogens
  • Genistein / pharmacology
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Humans
  • Hypoglycemic Agents
  • Isoflavones* / metabolism
  • Isoflavones* / pharmacology
  • Isoflavones* / therapeutic use
  • Kelch-Like ECH-Associated Protein 1 / metabolism
  • Myeloid Differentiation Factor 88 / metabolism
  • NF-E2-Related Factor 2 / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phytoestrogens / pharmacology
  • Proto-Oncogene Proteins c-akt / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Reperfusion
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Estrogens
  • Hypoglycemic Agents
  • Isoflavones
  • Kelch-Like ECH-Associated Protein 1
  • Myeloid Differentiation Factor 88
  • NF-E2-Related Factor 2
  • Phytoestrogens
  • Proto-Oncogene Proteins c-bcl-2
  • Estradiol
  • Genistein
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases

Grants and funding

This research received no external funding.